American Capital Management Inc. increased its stake in shares of ResMed Inc. (NYSE:RMD) by 0.6% in the fourth quarter, Holdings Channel reports. The firm owned 660,818 shares of the medical equipment provider’s stock after buying an additional 3,976 shares during the period. ResMed makes up approximately 3.4% of American Capital Management Inc.’s investment portfolio, making the stock its 9th largest position. American Capital Management Inc.’s holdings in ResMed were worth $55,965,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in ResMed during the 3rd quarter valued at about $113,000. YorkBridge Wealth Partners LLC increased its position in ResMed by 4.9% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 69 shares in the last quarter. Toronto Dominion Bank increased its position in ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after buying an additional 197 shares in the last quarter. BB&T Investment Services Inc. acquired a new position in ResMed during the 2nd quarter valued at about $214,000. Finally, Visionary Asset Management Inc. acquired a new position in ResMed during the 3rd quarter valued at about $214,000. Hedge funds and other institutional investors own 61.85% of the company’s stock.

Several research analysts recently issued reports on the company. Jefferies Group reaffirmed a “sell” rating and set a $56.00 target price on shares of ResMed in a research report on Thursday, October 12th. Needham & Company LLC raised ResMed from an “underperform” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating and set a $99.00 target price on the stock in a research report on Friday, January 5th. BMO Capital Markets upped their target price on ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research report on Friday, October 27th. Finally, Barclays upped their target price on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $71.71.

In related news, Director Peter C. Farrell sold 118,392 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the sale, the director now directly owns 306,615 shares of the company’s stock, valued at $25,357,060.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $84.50, for a total value of $105,625.00. Following the sale, the chief financial officer now directly owns 71,772 shares in the company, valued at $6,064,734. The disclosure for this sale can be found here. Insiders sold 158,929 shares of company stock worth $13,181,009 over the last three months. Corporate insiders own 1.77% of the company’s stock.

Shares of ResMed Inc. (NYSE RMD) traded down $1.17 during mid-day trading on Tuesday, hitting $87.51. The stock had a trading volume of 1,119,600 shares, compared to its average volume of 561,321. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $14,350.00, a price-to-earnings ratio of 35.43, a PEG ratio of 2.24 and a beta of 0.78. ResMed Inc. has a fifty-two week low of $62.64 and a fifty-two week high of $89.72.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.22. The business had revenue of $601.27 million for the quarter, compared to analyst estimates of $583.77 million. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.73 earnings per share. equities analysts expect that ResMed Inc. will post 3.04 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Thursday, February 8th will be issued a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.60%. ResMed’s dividend payout ratio is presently 56.68%.

COPYRIGHT VIOLATION NOTICE: This report was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2018/01/23/resmed-inc-rmd-position-raised-by-american-capital-management-inc.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.